buspirone has been researched along with Dyskinesia, Medication-Induced in 30 studies
Buspirone: An anxiolytic agent and serotonin receptor agonist belonging to the azaspirodecanedione class of compounds. Its structure is unrelated to those of the BENZODIAZAPINES, but it has an efficacy comparable to DIAZEPAM.
buspirone : An azaspiro compound that is 8-azaspiro[4.5]decane-7,9-dione substituted at the nitrogen atom by a 4-(piperazin-1-yl)butyl group which in turn is substituted by a pyrimidin-2-yl group at the N(4) position.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Prolactin response to buspirone was evaluated in patients with schizophrenia, with and without tardive dyskinesia (TD)." | 7.73 | Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. ( Conley, RR; Kelly, DL; Kim, YH; Lee, JG; Shim, JC, 2005) |
| "Pronounced oral dyskinesia developed in an elderly woman with advanced dementia who had been treated with buspirone for 3 days." | 4.77 | Oral dyskinesia associated with buspirone use in an elderly woman. ( Strauss, A, 1988) |
| "Prolactin response to buspirone was evaluated in patients with schizophrenia, with and without tardive dyskinesia (TD)." | 3.73 | Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia. ( Conley, RR; Kelly, DL; Kim, YH; Lee, JG; Shim, JC, 2005) |
| "Buspirone is a novel anxiolytic chemically unrelated to the benzodiazepines." | 2.66 | Buspirone in the treatment of tardive dyskinesia. ( Ross, CA, 1987) |
| "Buspirone is an anxiolytic drug and is a partial agonist for the serotonin 5-HT(1A) receptors as well as possessing low affinity and is an antagonist for the dopamine D(2) autoreceptors, with some evidence of a weak affinity to 5-HT(2) receptors." | 2.48 | Buspirone: what is it all about? ( Loane, C; Politis, M, 2012) |
| "The results suggest that compounds that indirectly facilitate 5-HT1 A receptor activation, such as citalopram, may be more effective therapeutics than direct 5-HT1 A receptor agonists because they exhibit similar anti-dyskinesia efficacy, while possessing a reduced side effect profile." | 1.42 | Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats. ( Bishop, C; Conti, MM; Lindenbach, D; Ostock, CY; Palumbo, N; Vilceus, N, 2015) |
| "In quinelorane-treated wild-type mice flibanserin as well as buspirone significantly reduced dystonia (p < 0." | 1.38 | The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice. ( Adamaszek, M; Beck, J; Ohm, S; Schwarz, J; Strecker, K; Wegner, F, 2012) |
| "Rats treated with haloperidol at a dose of 1 mg/kg exhibited impaired motor coordination and a decrease in exploratory activity." | 1.34 | Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study. ( Haleem, DJ; Haleem, MA; Samad, N, 2007) |
| "Rats treated with haloperidol at a dose of 1 mg/kg twice a day for 2 weeks displayed VCMs with twitching of facial musculature that increased in a time dependent manner as the treatment continued to 5 weeks." | 1.34 | Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats. ( Haleem, DJ; Haleem, MA; Samad, N, 2007) |
| " One patient developed a lasting problem of cervical-cranial dystonia and tremors after treatment with buspirone at a dosage of 40 mg/day for several weeks." | 1.29 | Persistent movement disorders induced by buspirone. ( Hening, W; LeWitt, PA; McHale, D; Walters, A, 1993) |
| "Buspirone was well tolerated by most subjects." | 1.29 | Buspirone in the treatment of tardive dyskinesia. ( Drevets, WC; Moss, LE; Neppe, VM, 1993) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (16.67) | 18.7374 |
| 1990's | 7 (23.33) | 18.2507 |
| 2000's | 7 (23.33) | 29.6817 |
| 2010's | 10 (33.33) | 24.3611 |
| 2020's | 1 (3.33) | 2.80 |
| Authors | Studies |
|---|---|
| Thomsen, M | 1 |
| Stoica, A | 1 |
| Christensen, KV | 1 |
| Fryland, T | 1 |
| Mikkelsen, JD | 1 |
| Hansen, JB | 1 |
| Shin, E | 2 |
| Lisci, C | 1 |
| Tronci, E | 1 |
| Fidalgo, C | 1 |
| Stancampiano, R | 1 |
| Björklund, A | 2 |
| Carta, M | 3 |
| Azkona, G | 1 |
| Sagarduy, A | 2 |
| Aristieta, A | 1 |
| Vazquez, N | 1 |
| Zubillaga, V | 1 |
| Ruíz-Ortega, JA | 2 |
| Pérez-Navarro, E | 1 |
| Ugedo, L | 2 |
| Sánchez-Pernaute, R | 1 |
| Politis, M | 2 |
| Wu, K | 1 |
| Loane, C | 2 |
| Brooks, DJ | 1 |
| Kiferle, L | 1 |
| Turkheimer, FE | 1 |
| Bain, P | 1 |
| Molloy, S | 1 |
| Piccini, P | 1 |
| Lindenbach, D | 1 |
| Palumbo, N | 1 |
| Ostock, CY | 1 |
| Vilceus, N | 1 |
| Conti, MM | 1 |
| Bishop, C | 1 |
| Levin, OS | 1 |
| Llorente, J | 1 |
| Miguelez, C | 1 |
| Morera-Herreras, T | 1 |
| Paquette, MA | 1 |
| Foley, K | 1 |
| Brudney, EG | 1 |
| Meshul, CK | 1 |
| Johnson, SW | 1 |
| Berger, SP | 1 |
| Howland, RH | 1 |
| Strecker, K | 1 |
| Adamaszek, M | 1 |
| Ohm, S | 1 |
| Wegner, F | 1 |
| Beck, J | 1 |
| Schwarz, J | 1 |
| Garcia, J | 1 |
| Winkler, C | 1 |
| Pavlovic, ZM | 1 |
| Lundblad, M | 1 |
| Usiello, A | 1 |
| Håkansson, K | 1 |
| Fisone, G | 1 |
| Cenci, MA | 1 |
| Shim, JC | 1 |
| Kim, YH | 1 |
| Kelly, DL | 1 |
| Lee, JG | 1 |
| Conley, RR | 1 |
| Haleem, DJ | 2 |
| Samad, N | 2 |
| Haleem, MA | 2 |
| LeWitt, PA | 1 |
| Walters, A | 1 |
| Hening, W | 1 |
| McHale, D | 1 |
| Moss, LE | 1 |
| Neppe, VM | 2 |
| Drevets, WC | 1 |
| Bonifati, V | 1 |
| Fabrizio, E | 1 |
| Cipriani, R | 1 |
| Vanacore, N | 1 |
| Meco, G | 1 |
| Queiroz, CM | 2 |
| Frussa-Filho, R | 2 |
| Alcântara, FB | 1 |
| Yagüe, AM | 1 |
| Bibancos, T | 1 |
| Brody, D | 1 |
| Adler, LA | 1 |
| Kim, T | 1 |
| Angrist, B | 1 |
| Rotrosen, J | 1 |
| Kleedorfer, B | 1 |
| Lees, AJ | 1 |
| Stern, GM | 1 |
| Rock, NL | 1 |
| Lydiard, RB | 1 |
| Ross, CA | 1 |
| Strauss, A | 1 |
| Simpson, GM | 1 |
| Singh, H | 1 |
2 reviews available for buspirone and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Buspirone: what is it all about?
Topics: Animals; Buspirone; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; Humans; Mental Disor | 2012 |
Oral dyskinesia associated with buspirone use in an elderly woman.
Topics: Aged; Aged, 80 and over; Buspirone; Dementia; Dyskinesia, Drug-Induced; Female; Humans; Mouth Diseas | 1988 |
3 trials available for buspirone and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Serotonergic mechanisms responsible for levodopa-induced dyskinesias in Parkinson's disease patients.
Topics: Aged; Antiparkinson Agents; Buspirone; Case-Control Studies; Dopamine; Double-Blind Method; Dyskines | 2014 |
Buspirone in levodopa-induced dyskinesias.
Topics: Aged; Buspirone; Double-Blind Method; Dyskinesia, Drug-Induced; Female; Humans; Levodopa; Male; Midd | 1994 |
Buspirone in the treatment of tardive dyskinesia.
Topics: Anti-Anxiety Agents; Buspirone; Clinical Trials as Topic; Dopamine; Dyskinesia, Drug-Induced; Humans | 1987 |
25 other studies available for buspirone and Dyskinesia, Medication-Induced
| Article | Year |
|---|---|
Synergistic effect of serotonin 1A and serotonin 1B/D receptor agonists in the treatment of L-DOPA-induced dyskinesia in 6-hydroxydopamine-lesioned rats.
Topics: Amantadine; Animals; Antiparkinson Agents; Buspirone; Dyskinesia, Drug-Induced; Levodopa; Oxazolidin | 2022 |
The anti-dyskinetic effect of dopamine receptor blockade is enhanced in parkinsonian rats following dopamine neuron transplantation.
Topics: Amphetamine; Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Benzazepines; Buspirone; Disease | 2014 |
Buspirone anti-dyskinetic effect is correlated with temporal normalization of dysregulated striatal DRD1 signalling in L-DOPA-treated rats.
Topics: Animals; Anti-Dyskinesia Agents; Antiparkinson Agents; Buspirone; Corpus Striatum; Cyclic AMP Respon | 2014 |
Side effect profile of 5-HT treatments for Parkinson's disease and L-DOPA-induced dyskinesia in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antiparkinson Agents; Buspirone; Citalopram; Dyskin | 2015 |
[The use of buspirone in clinical practice].
Topics: Anti-Anxiety Agents; Anxiety; Buspirone; Depression; Dyskinesia, Drug-Induced; Humans; Parkinson Dis | 2015 |
Buspirone requires the intact nigrostriatal pathway to reduce the activity of the subthalamic nucleus via 5-HT1A receptors.
Topics: Action Potentials; Adrenergic Agents; Adrenergic Uptake Inhibitors; Animals; Buspirone; Desipramine; | 2016 |
The sigma-1 antagonist BMY-14802 inhibits L-DOPA-induced abnormal involuntary movements by a WAY-100635-sensitive mechanism.
Topics: Animals; Buspirone; Disease Models, Animal; Dopamine Agents; Dose-Response Relationship, Drug; Dyski | 2009 |
Drug therapies for tardive dyskinesia: Part 1.
Topics: Amantadine; Antipsychotic Agents; Buspirone; Dopamine Agents; Dyskinesia, Drug-Induced; Humans; Move | 2011 |
The 5-HT1A-receptor agonist flibanserin reduces drug-induced dyskinesia in RGS9-deficient mice.
Topics: Animals; Benzimidazoles; Buspirone; Dose-Response Relationship, Drug; Drug Administration Schedule; | 2012 |
Serotonergic and dopaminergic mechanisms in graft-induced dyskinesia in a rat model of Parkinson's disease.
Topics: 5,6-Dihydroxytryptamine; Adrenergic Agents; Amphetamine; Analysis of Variance; Animals; Antiparkinso | 2012 |
Buspirone to improve compliance in venlafaxine-induced movement disorder.
Topics: Antidepressive Agents, Second-Generation; Buspirone; Compliance; Cyclohexanols; Depressive Disorder, | 2004 |
Pharmacological validation of a mouse model of l-DOPA-induced dyskinesia.
Topics: Adenosine A2 Receptor Agonists; Adrenergic Agents; Amantadine; Animals; Antiparkinson Agents; Basal | 2005 |
Tardive dyskinesia predicts prolactin response to buspirone challenge in people with schizophrenia.
Topics: Adult; Antipsychotic Agents; Buspirone; Dopamine D2 Receptor Antagonists; Dyskinesia, Drug-Induced; | 2005 |
Reversal of haloperidol-induced extrapyramidal symptoms by buspirone: a time-related study.
Topics: Animals; Anti-Anxiety Agents; Antipsychotic Agents; Ataxia; Buspirone; Catalepsy; Dyskinesia, Drug-I | 2007 |
Reversal of haloperidol-induced tardive vacuous chewing movements and supersensitive somatodendritic serotonergic response by buspirone in rats.
Topics: 8-Hydroxy-2-(di-n-propylamino)tetralin; Animals; Antipsychotic Agents; Buspirone; Chromatography, Hi | 2007 |
Persistent movement disorders induced by buspirone.
Topics: Antipsychotic Agents; Buspirone; Dyskinesia, Drug-Induced; Dystonia; Humans; Male; Middle Aged; Phon | 1993 |
Buspirone in the treatment of tardive dyskinesia.
Topics: Adult; Aged; Antipsychotic Agents; Buspirone; Dose-Response Relationship, Drug; Dyskinesia, Drug-Ind | 1993 |
Effects of buspirone on an animal model of tardive dyskinesia.
Topics: Adrenergic Uptake Inhibitors; Animals; Buspirone; Disease Models, Animal; Dopamine; Dyskinesia, Drug | 1999 |
Acute buspirone abolishes the expression of behavioral dopaminergic supersensitivity in mice.
Topics: Animals; Anti-Anxiety Agents; Behavior, Animal; Buspirone; Dopamine; Dopamine Antagonists; Drug Hype | 2002 |
Effects of buspirone in seven schizophrenic subjects.
Topics: Antipsychotic Agents; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Humans; Psychi | 1990 |
Buspirone in the treatment of levodopa induced dyskinesias.
Topics: Adult; Aged; Apomorphine; Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Hu | 1991 |
Possible adverse effects of buspirone when used with other psychotropic drugs.
Topics: Adult; Akathisia, Drug-Induced; Bipolar Disorder; Buspirone; Dose-Response Relationship, Drug; Drug | 1990 |
Buspirone revisited.
Topics: Aged; Aged, 80 and over; Antipsychotic Agents; Buspirone; Dyskinesia, Drug-Induced; Female; Humans; | 1989 |
High-dose buspirone in case of tardive dyskinesia.
Topics: Buspirone; Drug Therapy, Combination; Dyskinesia, Drug-Induced; Female; Humans; Middle Aged; Nadolol | 1989 |
Buspirone and dyskinesia.
Topics: Aged; Buspirone; Dyskinesia, Drug-Induced; Female; Humans; Research Design | 1988 |